GlassScriptPhysician profile
Robert J Callahan
NPI 1174532865
$3,916.47
in general payments reported to CMS, 2019-2025
36 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $566 · 2021: $853 · 2022: $827 · 2023: $748 · 2024: $363 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.10 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.99 | 2019-2025 | Jardiance |
| Pfizer INC. | $383.40 | 2019-2024 | |
| Lilly USA, LLC | $319.55 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $294.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $183.66 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $178.51 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $112.76 | 2020-2024 | Yupelri |
| Allergan, INC. | $109.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $105.86 | 2020-2024 | Farxiga, Xigduo |
| Merck Sharp & Dohme LLC | $78.95 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.92 | 2021-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $60.62 | 2021-2022 | |
| Amarin Pharma, INC. | $56.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.37 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $51.93 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $50.08 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $47.49 | 2022 | |
| Abbott Laboratories | $45.97 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $45.44 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $38.08 | 2021 | |
| Amgen INC. | $37.43 | 2019-2022 | |
| Medtronic, INC. | $36.84 | 2021 | |
| Eisai INC. | $29.82 | 2020-2021 | |
| Circassia INC. | $25.20 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.73 | 2023 | Opsumit, Uptravi |
| Astellas Pharma US INC | $20.48 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $18.25 | 2024 | |
| Lundbeck LLC | $15.52 | 2023 | Vyepti |
| Almatica Pharma LLC | $14.40 | 2023 | Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $14.32 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.69 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.05 | 2023 | Quviviq |
| Genentech USA, INC. | $13.00 | 2021 | |
| Boston Scientific Corporation | $11.86 | 2019 | |
| Therapeuticsmd, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.